| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfb0281008cb570feea037cd350c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbdae384a9f1ad0588422c89ddc71a00 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-20 |
| filingDate |
2011-05-13^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a49eab9c9f58c03ccd6cdb25ebd66a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d606c6e3b0c188d6eccc349a4cef7825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e20ff051312a9eef5d7b062189756888
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97ae191d5f33e4060cf71c7ae4765fe6 |
| publicationDate |
2020-05-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3650041-A1 |
| titleOfInvention |
Ospa chimeras and use thereof in vaccines |
| abstract |
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis. |
| priorityDate |
2010-05-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |